Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2023-08-27 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Annual Report for year ended 30 June 2023 62 pages 3.3MB
Regulatory Filings
2023-08-27 English
Full Year Results FY2023 4 pages 271.3KB
Annual Report Classification · 95% confidence The document is titled 'FULL YEAR RESULTS FY2023' and mentions the release of the 2023 financial year audited accounts and Annual Report. It contains detailed financial and operational information about the company's research and development costs, cash position, program progress, and outlook. The document is about 9,254 characters long, which is substantial and contains substantive financial data and management commentary. It is not merely an announcement of a report or a certification. The content aligns with a comprehensive yearly report covering company activity and full financial performance, which fits the definition of an Annual Report (10-K).
2023-08-27 English
Quarterly Activities Report and Appendix 4C 10 pages 493.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report and Appendix 4C' and covers the quarter ending 30 June 2023. It includes detailed operational updates on drug development programs, financial summaries including cash flow statements, and an Appendix 4C cash flow report as required by ASX Listing Rule 4.7B. The content includes substantive financial data such as cash position, operating cash flows, and expenditure breakdowns, as well as detailed business activities and outlook. This matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial and operational information for a period shorter than a full fiscal year. The document is about 15,000 characters long, well beyond a brief announcement, and contains actual financial statements and analysis, not just a notice or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2023-07-27 English
Nyrada Review of Operating Costs 2 pages 223.4KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Nyrada Inc regarding a review of operating costs and voluntary reduction of director fees. It does not contain financial statements, detailed financial data, or comprehensive management discussion. The document is relatively short (3640 characters) and serves as an update on cost management initiatives rather than a full financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, or Management Report. It also does not fit categories like Board/Management changes, Capital updates, or Legal Proceedings. The content is a general corporate announcement about operating cost review and board fee reductions, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2023-07-19 English
Cholesterol-Lowering Program Update 2 pages 225.2KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Nyrada Inc regarding an update on their cholesterol-lowering drug development program. It discusses adverse findings in a toxicology study that preclude the drug candidate from clinical evaluation and defers the Phase I/IIa study. The content is a corporate update on a specific program development and does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a regulatory filing or certification. The document is an operational update related to the company's drug development progress, which fits best under the category of a general regulatory announcement or corporate update. Given the absence of financial data or detailed report content, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-06-25 English
Brain Injury Program Preclinical Development Update 3 pages 264.6KB
Capital/Financing Update Classification · 90% confidence The document is a corporate announcement providing an update on the preclinical development of a new brain injury drug candidate by Nyrada Inc. It discusses the selection of a new lead compound, plans for upcoming studies, and participation in a scientific symposium. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on research and development progress and strategic updates rather than financial results or regulatory filings. It is not a report itself but an update announcement. Given the nature of the content, it best fits the category of a Capital/Financing Update (CAP) as it relates to the development progress and funding status of a drug candidate, which is a form of corporate update on capital deployment and project advancement. The document length and detail exceed a brief factsheet but do not constitute a full financial or management report. Therefore, the classification is CAP with high confidence.
2023-06-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.